drug trial

Novel treatment for Prader-Willi syndrome being tested at VUMC

A novel treatment for Prader-Willi syndrome, one of the most common genetic causes of obesity, may improve the insatiable hunger that patients with the disorder experience.

New drugs approved to fight idiopathic pulmonary fibrosis

The Vanderbilt Idiopathic Pulmonary Fibrosis Center played a key role in testing the first two drugs approved by the FDA for the treatment of idiopathic pulmonary fibrosis (IPF).

Study tracks new end-stage renal disease therapy

Researchers in Vanderbilt’s Division of Nephrology conducted a Phase 3 clinical trial to test the safety and efficacy of a new drug to treat patients with end-stage renal disease.